Pharmaceutical Business Investment Opportunities in India

1. The business operates in the generic pharmaceuticals industry, offering a wide range of tablets except narcotics-related products. 2. Located in Baddi, the company adheres to Good Manufacturing Practice (GMP) and World Health Organization (WHO) Drugs and Cosmetics guidelines for its machinery and facilities. 3. The business boasts Microbiological and Chemical laboratories compliant with the latest guidelines, ensuring quality control and regulatory compliance. 5. The owner, who has prior experience in manufacturing and runs a successful marketing company, possesses valuable connections within the pharmaceutical industry. 6. With plans to operate at 50% capacity in the next 6 months, the business projects sales of over INR 50 crores, with an expected net profit of INR 8 crores, reflecting a strong revenue and profitability outlook. 7. The business benefits from the owner's industry expertise and established relationships with pharmaceutical clients, which may contribute to its growth and success. 8. The focus on generic pharmaceuticals and compliance with industry standards positions the business to capitalize on the growing demand for affordable and accessible medication. 9. The company was incorporated in 2019 but was not able to start operations due to the covid crisis, the promoters are looking to start the business now and are also work on the lab to ensure that the required licenses are in place.

- We deal with more than 1,500 customers. - Customers include pharmacies, hospitals, and other wholesalers. - Our customer base and revenue have grown by 20% every year. - Equal revenue split across all customer categories. - We are leading distributors for Cipla, Sun Pharma Alkem, and 70 more companies. - We are a C/F for Alkem, Abbot, Aristo, Laborate, Aqualab, and Troikaa. - The owner has an experience of 34 years in the industry. - The revenue seems high due to the high volume as we are wholesalers. However, our margins are very thin at about 5-6%.

- Contract manufacturer of antibiotic tablets, capsules, and syrups. - We have a huge capacity to manufacture the Potassium Clavulanate section and last year's turnover was INR 7 crore. - We can do more than INR 25 crore turnover but looking for working capital and some investments. - Production capacity (daily): • 20 lakh tablets. • 20,000 dry syrups. • 5 lakh capsules. - The plant has 50 regular employees and about 50 contract workers. - The investor gets a 50% share in this unit. This means they get a 50% share of all the assets in this unit. - We as a group have 5 other units and have registered this specific unit as a separate legal entity.